Pfizer’s COVID-19 Vaccine is 95% Effective in Final Test
“The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.”
|
Listen to this article
|
Pfizer and BioNTech found its COVID-19 is 95% effective in the last trial run, “meeting all primary efficacy endpoints.”
The vaccine also showed signs of safety and met all the requirements for the FDA to approve its use as soon as possible.
From Pfizer:
- Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group
- Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
- Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
- Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
- Companies plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe
- The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021
- Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world
There are four Pfizer facilities that take part in manufacturing and distribution: St. Louis, Andover, Kalamazoo, and Puurs, Belgium.
The global supply will come from BioNTech’s German sites.
Moderna announced on Monday that its COVID-19 vaccine is 94.5% effective. It has one advantage over the Pfizer vaccine:
A key advantage of Moderna’s vaccine is that it does not need ultra-cold storage like Pfizer’s, making it easier to distribute. Moderna expects it to be stable at standard refrigerator temperatures of 2 to 8 degrees Celsius (36 to 48°F) for 30 days and it can be stored for up to 6 months at -20 degrees Celsius.
Pfizer’s vaccine must be shipped and stored at minus 70 degrees Celsius, the sort of temperature typical of an Antarctic winter. At standard refrigerator temperatures, it can be stored for up to five days.
RELEASE BOTH NOW.
DONATE
Donations tax deductible
to the full extent allowed by law.
Ron Coleman
Comments
The desire to believe this is strong. That being said, there is history of misleading and outright lying by government entities. Let’s hope that the projections are valid.
The vaccine need not be 95% effective. If it is 70% effective (similar to influenza vaccine in an average year), the incidence of COVID infection will drop substantially. Like influenza, some people will still be infected and some (mostly elderly, frail, and/or immunocompromised) will die. But COVID will be much less of a scourge. That in turn will allow us to re-open our country, if only because it will take all pressure off our health care system.
Future Headline: “Democrat governors declare lockdowns must continue until Covid-19 vaccine is 150% effective!”
I’m concerned there aren’t enough transgender scientists of color working on this project.
How many Pfizer and Moderna executives are on the Biden transition team? How many big tech executive are on the Biden transition team since they helped Biden win by censoring negative news about him and his family.
Leave a Comment